Please login to the form below

Not currently logged in
Email:
Password:

PMEA 2016 finalists announced

AbbVie, Bayer, Celgene and Novartis are up for the prestigious Company of the Year

PMEA 2016The finalists for PMEA 2016 have been announced, with some 49 entries making the cut thanks to their focus on improving patient outcomes.

The PMEA awards programme is designed to reward responsible customer-centric business practices that ensure treatments and advice provide patients with meaningful outcomes.

This year, for the first time, the awards will also recognise the best of the agencies behind the pharma clients with the new PMEA Support Agency of the Year award.

Shortlisted for their contributions, Aurora, Bedrock, Complete HealthVizion, GCI Health, Lucid Group and Uptake Strategies are all in the running for the inaugural agency grand prize.

Meanwhile, in contention for the coveted Company of the Year award are AbbVieBayer, Celgene and Novartis.

In the patient and customer-centric education and support programmes category, AstraZeneca's 'Life after heart attack' project and the British Society of Gastroenterology's 'IBD Registry Roadshow' are among those with a chance of winning.

The PMEA 2016 awards will take place on Wednesday 23 November at The Lancaster Hotel in London.

Article by
Rebecca Clifford

18th October 2016

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...